Literature DB >> 25308300

Reasonable incomplete revascularisation after percutaneous coronary intervention: the SYNTAX Revascularisation Index.

Philippe Généreux1, Carlos M Campos, Mayank Yadav, Tullio Palmerini, Adriano Caixeta, Ke Xu, Dominic P Francese, George D Dangas, Roxana Mehran, Martin B Leon, Patrick W Serruys, Gregg W Stone.   

Abstract

AIMS: Incomplete revascularisation is common after percutaneous coronary intervention (PCI). While the absolute amount of residual coronary artery disease (CAD) after PCI has been shown to be associated with worse outcomes, whether the proportion of treated CAD is prognostically important remains to be determined. We sought to quantify the proportion of CAD burden treated by PCI and to evaluate its impact on outcomes using a new prognostic instrument - the SYNTAX Revascularisation Index (SRI). METHODS AND
RESULTS: The baseline SYNTAX score (bSS) and residual SYNTAX score (rSS) were determined from 2,618 angiograms of patients enrolled in the prospective ACUITY trial. The SRI was then calculated for each patient using the following formula: SRI=(1-[rSS/bSS])×100. Outcomes were examined according to three SRI groups (SRI=100% [complete revascularisation], 50-99%, and <50%). The median bSS was nine (IQR 5, 16), and after PCI the median rSS was one (IQR 0, 6). The median SRI was 85% (IQR 50, 100), and was 100% in 1,079 patients (41.2%), 50-99% in 907 patients (34.6%), and <50% in 632 patients (24.1%). One-year adverse outcomes, including death, were inversely proportional to the SRI. An SRI cut-off of <80% (present in 1,189 [45.4%] patients after PCI) had the best prognostic accuracy for prediction of death (area under the curve 0.60, 95% confidence interval [CI]: 0.53-0.67, p<0.0001). By multivariable analysis, SRI was an independent predictor of one-year mortality (hazard ratio [HR] 2.17, 95% CI: 1.05-4.35, p=0.03). However, when compared to other scores, the rSS showed superior accuracy and predictive capability for one-year mortality.
CONCLUSIONS: The SRI is a newly described method for quantifying the proportion of CAD burden treated by PCI. Given its correlation with mortality, and pending external validation, the SRI may be useful in assessing the degree of revascularisation after PCI, with SRI ≥80% representing a reasonable goal. However, the rSS showed superior predictive capability for one-year mortality.

Entities:  

Mesh:

Year:  2015        PMID: 25308300     DOI: 10.4244/EIJY14M10_05

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  9 in total

Review 1.  Can We Improve the Outcomes of Multivessel Disease Using Modified SYNTAX and Residual SYNTAX Scores?

Authors:  Alfredo E Rodriguez; Carlos Fernandez-Pereira; Juan Mieres; Javier Mendoza; Florencia Sartori
Journal:  Curr Cardiol Rep       Date:  2017-03       Impact factor: 2.931

2.  Risk Burden of Coronary Perforation in Chronic Total Occlusion Recanalization: Latin American CTO Registry Analysis.

Authors:  Marcelo Harada Ribeiro; Carlos M Campos; Lucio Padilla; Antonio Carlos B da Silva; João Eduardo T de Paula; Marco Alcantara; Ricardo Santiago; Franklin Hanna; Franciele R da Silva; Karlyse C Belli; Lorenzo Azzalini; Pedro P de Oliveira; Gustavo N Araujo; Vincenzo Sucato; Kambis Mashayekhi; Alfredo R Galassi; Alexandre Abizaid; Alexandre Quadros
Journal:  J Am Heart Assoc       Date:  2022-06-03       Impact factor: 6.106

Review 3.  Impact of Incomplete Percutaneous Revascularization in Patients With Multivessel Coronary Artery Disease: A Systematic Review and Meta-Analysis.

Authors:  Vinayak Nagaraja; Sze-Yuan Ooi; James Nolan; Adrian Large; Mark De Belder; Peter Ludman; Rodrigo Bagur; Nick Curzen; Takashi Matsukage; Fuminobu Yoshimachi; Chun Shing Kwok; Colin Berry; Mamas A Mamas
Journal:  J Am Heart Assoc       Date:  2016-12-16       Impact factor: 5.501

4.  New Predictors of Early and Late Outcomes after Primary Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction and Unprotected Left Main Coronary Artery Culprit Lesion.

Authors:  Cãlin Homorodean; Adrian Corneliu Iancu; Daniel Leucuţa; Şerban Bãlãnescu; Ioana Mihaela Dregoesc; Mihai Spînu; Mihai Ober; Dan Tãtaru; Maria Olinic; Dan Bindea; Dan Olinic
Journal:  J Interv Cardiol       Date:  2019-03-18       Impact factor: 2.279

Review 5.  Challenges and Management of Acute Coronary Syndrome in Cancer Patients.

Authors:  Isabela Bispo Santos da Silva Costa; Fernanda Thereza de Almeida Andrade; Diego Carter; Vinicius B Seleme; Maycon Santos Costa; Carlos M Campos; Ludhmila Abrahão Hajjar
Journal:  Front Cardiovasc Med       Date:  2021-06-09

6.  Novel predictors of outcome after coronary angioplasty with rotational atherectomy. Not only low ejection fraction and clinical parameters matter.

Authors:  Piotr Kübler; Wojciech Zimoch; Michał Kosowski; Brunon Tomasiewicz; Oscar Rakotoarison; Artur Telichowski; Krzysztof Reczuch
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-03-22       Impact factor: 1.426

7.  Impact of Residual SYNTAX Score and Its Derived Indexes on Clinical Outcomes after Percutaneous Coronary Intervention: Data from a Large Single Center.

Authors:  Ying Song; Zhan Gao; Xiao-Fang Tang; Ping Jiang; Jing-Jing Xu; Yi Yao; Jian-Xin Li; Xue-Yan Zhao; Shu-Bin Qiao; Yue-Jin Yang; Run-Lin Gao; Bo Xu; Jin-Qing Yuan
Journal:  Chin Med J (Engl)       Date:  2018-06-20       Impact factor: 2.628

8.  Relationship between White Blood Count to Mean Platelet Volume Ratio and Clinical Outcomes and Severity of Coronary Artery Disease in Patients Undergoing Primary Percutaneous Coronary Intervention.

Authors:  Altekin Refik Emre; Kilinc Ali Yasar; Yanikoglu Atakan; Cicekcibasi Orhan; Kucuk Murathan
Journal:  Cardiovasc Ther       Date:  2020-08-13       Impact factor: 3.023

9.  Prognostic Value of the Residual SYNTAX Score on In-Hospital and Follow-Up Clinical Outcomes in ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Interventions.

Authors:  Refik Emre Altekin; Ali Yasar Kilinc; Mehdi Onac; Orhan Cicekcibasi
Journal:  Cardiol Res Pract       Date:  2020-10-29       Impact factor: 1.866

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.